Balanced news tone
News Sentiment
TRDA sentiment intelligence
Entrada Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
57 relevant articles
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value.
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
80/100 classification
One-week reaction
-0.4%
Price digesting
Trend fit
Trend inactive
-2.8% over four weeks
Fair value
-43.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
32
Negative
13
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Moomoo
Direct company coverage
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10
Roth MKM has reiterated its Buy rating for Entrada Therapeutics (TRDA.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 15 Jul 2026 13:11
- Source
- Moomoo
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stock Traders Daily
Direct company coverage
Why (TRDA) Price Action Is Critical for Tactical Trading
This article analyzes Entrada Therapeutics Inc. (NASDAQ: TRDA) using AI models to provide tactical trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but strong mid and long-term support signals, offering specific entry
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 10:09
- Source
- Stock Traders Daily
The National Law Review
Direct company coverage
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of investors. This investigation follows a significant stock price drop of 57.27% on May 7, 2026, after the company announced "positive" Phase 1/2 clin
- Tone
- Negative 20/100
- Event
- Regulatory and legal
- Published
- 03 Jul 2026 21:10
- Source
- The National Law Review
Stock Traders Daily
Direct company coverage
Understanding Momentum Shifts in (TRDA)
This article analyzes Entrda Therapeutics Inc. (NASDAQ: TRDA) using AI models, highlighting strong sentiment across all horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, with speci
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 08:12
- Source
- Stock Traders Daily
TradingView
Direct company coverage
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This article displays the "Price to book forward" metric for Entrada Therapeutics, Inc. (NASDAQ: TRDA). It appears to be a financial data point presented within the TradingView platform, with no additional textual analysis or details provided. The content is minimalist, focusing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 08:39
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This article provides a brief financial overview for Entrada Therapeutics, Inc. (NASDAQ: TRDA), focusing on its forward price-to-earnings ratio. The content primarily lists navigation and platform features of TradingView, where this financial data is presumably presented, rather
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 08:10
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA
This page provides financial information for Entrada Therapeutics, Inc. (NASDAQ: TRDA) on TradingView, specifically focusing on its price-to-sales forward ratio. It also lists various features and services offered by TradingView, including market data, analytical tools, community
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 19:40
- Source
- TradingView
TradingView
Direct company coverage
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA)
This article provides an overview of Entrada Therapeutics, Inc. (NASDAQ: TRDA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and past financial result
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 03:39
- Source
- TradingView
TradingView
Direct company coverage
TRDA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Entrada Therapeutics, Inc. (TRDA) stock, including current analyst price targets, ratings, and financial data. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA, along with frequently asked questi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 23 Jun 2026 21:40
- Source
- TradingView
Intellectia AI
Direct company coverage
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Entrada Therapeutics Inc (TRDA), detailing its revenue breakdown, profitability margins, and a competitive comparison. TRDA boasts a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 21 Jun 2026 03:39
- Source
- Intellectia AI
TradingKey
Direct company coverage
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Entrada Therapeutics Inc (TRDA), highlighting its current valuation score of 6.99 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.77, which is significantly below its recent high. The artic
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 13:40
- Source
- TradingKey
TradingKey
Direct company coverage
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Entrada Therapeutics Inc.'s (TRDA) revenue breakdown. It indicates that relevant data for business segments and profit contribution have not yet been disclosed by the company. However, it does provide a revenue figure for the United State
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 11:10
- Source
- TradingKey
Stock Traders Daily
Direct company coverage
Avoiding Lag: Real-Time Signals in (TRDA) Movement
This article analyzes Entrada Therapeutics Inc. (
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 18 Jun 2026 07:28
- Source
- Stock Traders Daily
TradingKey
Direct company coverage
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Entrada Therapeutics Inc (TRDA) has an earnings forecast score of 8.50, ranking 107th in its industry, with an average analyst price target of $16.50. Analysts predominantly rate TRDA as a "Buy," forecasting an expected revenue of 411.43K for the next quarter and an EPS of -$1.05
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 17 Jun 2026 18:09
- Source
- TradingKey
TradingKey
Direct company coverage
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis
Entrada Therapeutics Inc (TRDA) currently holds a financial score of 6.01, ranking 301st out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company's latest quarterly revenue decreased by 95.74% year-o
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 17 Jun 2026 01:09
- Source
- TradingKey
The Globe and Mail
Direct company coverage
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
Entrada Therapeutics Inc. stockholders approved key measures at their annual meeting, including the election of two Class II directors, Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D., and the ratification of Ernst & Young LLP as their independent auditor. Shareholders also appro
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 14 Jun 2026 14:39
- Source
- The Globe and Mail
The Globe and Mail
Direct company coverage
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)
Oppenheimer has reiterated a Buy rating on Entrada Therapeutics Inc (TRDA) with a price target of $23.00, following an earlier report by Roth MKM which also maintained a Buy rating and a $10.00 price target. The company recently reported a quarterly revenue of $875 thousand and a
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 14 Jun 2026 11:40
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity
Entrada Therapeutics director and 10% owner Kush Parmar was granted 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options will vest on the earlier of the one-year anniversary of June 10, 2026, or the company’s next annual meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 21:49
- Source
- Stock Titan
Stock Titan
Direct company coverage
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97
Entrada Therapeutics (TRDA) director Gina Chapman was granted 19,000 stock options at an exercise price of $5.97 per share. These options will vest on the earlier of one year from June 10, 2026, or the company's next annual meeting, and are set to expire on June 10, 2036. The tra
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 21:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading
Entrada Therapeutics director Radhakrishnan Maha was granted 19,000 stock options, allowing him to purchase common stock at an exercise price of $5.97 per share. These options, granted at no cost, will vest on the earlier of June 10, 2027, or the company's next annual meeting, an
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options
Entrada Therapeutics director Peter S. Kim received a grant of 19,000 stock options with an exercise price of $5.97 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027, or the company's next annual meeting of stockholders. The transaction was
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 04:10
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)
This article highlights contrasting analyst sentiments for Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) within the healthcare sector. Entrada Therapeutics receives a Strong Buy consensus with significant upside potential, based on a Buy rating from Guggenheim and Roth MKM. In
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 09 Jun 2026 15:40
- Source
- The Globe and Mail
Stock Traders Daily
Direct company coverage
Discipline and Rules-Based Execution in TRDA Response
This article provides an in-depth analysis of Entrada Therapeutics Inc. (NASDAQ: TRDA) as of June 7, 2026, highlighting weak near-term sentiment but strong mid and long-term signals. It presents AI-generated trading strategies including position, momentum, and risk hedging, along
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 07 Jun 2026 05:40
- Source
- Stock Traders Daily
Simply Wall Street
Direct company coverage
Entrada Therapeutics (NasdaqGM:TRDA) Stock Forecast & Analyst Predictions
Entrada Therapeutics (TRDA) is expected to see its earnings decline by 1.6% per annum, while revenue is projected to grow by 44% yearly. Analysts forecast a net loss per share of US$4.09 next year, leading to a recent consensus price target reduction to US$18.75. The company is a
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 05 Jun 2026 21:39
- Source
- Simply Wall Street
PR Newswire
Direct company coverage
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (TRDA) on behalf of investors. This investigation follows a significant stock price drop after Entrada announced Phase 1/2 clinical study results for a Duchenne treatment, which, d
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 04 Jun 2026 13:39
- Source
- PR Newswire
GlobeNewswire
Direct company coverage
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 11:00
- Source
- GlobeNewswire
Investing.com
Direct company coverage
Entrada gets clearance to escalate dose in DMD trial
Entrada Therapeutics Inc. (NASDAQ:TRDA) has received clearance from an independent Data Monitoring Committee to escalate the dose in Cohort 2 of its ELEVATE-45-201 study for Duchenne muscular dystrophy (DMD) to 10 mg/kg, up from 5 mg/kg. The decision follows a review of safety an
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 02 Jun 2026 11:39
- Source
- Investing.com
Pluang
Direct company coverage
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial
Entrada Therapeutics has announced that an independent Data Monitoring Committee has approved an increase in the dose to 10 mg/kg for Cohort 2 in its Phase 1/2 trial for Duchenne muscular dystrophy. This decision follows positive safety and pharmacokinetic reviews of subjects tre
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 11:39
- Source
- Pluang